Back to Awarded Treatment Trials
Awarded Trial: 02T-241
Grant ID
02T-241
Illness
Schizophrenia and Alcohol Dependence
Primary Drug/Intervention
Glycine
Primary Dosage
60 grams
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Petrakis
Sample Size
46
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
Alcohol use, PANSS, CDS, movement disorder scales, quality of life scales, cognitive battery
Results
This trial randomized 20 patients with schizophrenia and alcohol abuse to glycine or placebo plus their regular medication for 12 weeks. The primary outcome was alcohol craving and drinking, and there were no differences between those on glycine or placebo. The secondary outcome was schizophrenia symptoms as measured by PANSS; patients on glycine had a nonsignificant reduction in both positive and negative symptoms.
Publication
N/A
Link
N/A
PI Name
Ismene Petrakis
Degree
MD
Center
VA CT Heatlhcare System, Research / 116 A
Institution
Yale University School of Medicine
Address
950 Campbell Ave
City or Town
West Haven
State or Province
CT
Zip or Postal Code
6516
Country
USA
Email Address
ismene.petrakis@yale.edu